<SEC-DOCUMENT>0001193125-11-137610.txt : 20110512
<SEC-HEADER>0001193125-11-137610.hdr.sgml : 20110512
<ACCEPTANCE-DATETIME>20110512161852
ACCESSION NUMBER:		0001193125-11-137610
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20110512
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110512
DATE AS OF CHANGE:		20110512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD RESEARCH CORP
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21898
		FILM NUMBER:		11836050

	BUSINESS ADDRESS:	
		STREET 1:		201 SOUTH LAKE AVENUE
		STREET 2:		SUITE 703
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91101
		BUSINESS PHONE:		626-304-3400

	MAIL ADDRESS:	
		STREET 1:		201 SOUTH LAKE AVENUE
		STREET 2:		SUITE 703
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91101

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO SECTION 13 OR 15(D) OF THE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT OF 1934
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): May&nbsp;12, 2011 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Arrowhead Research Corporation </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0-21898
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission File Number) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>46-0408024</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction of incorporation)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer Identification No.)</B></FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>225 South Lake Avenue, Suite 300, Pasadena, CA 91101 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of
principal executive offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code (626)&nbsp;304-3400
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4 (c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;2.02 Results of Operations and Financial Condition </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On May&nbsp;12, 2011, Arrowhead Research Corporation announced and commented on its financial results for the quarter ended March&nbsp;31, 2011. A copy of
the press release is furnished herewith as Exhibit&nbsp;99.1 and incorporated by reference herein. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>In accordance with General Instruction
B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit&nbsp;99.1, shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange
Act&#148;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof,
except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial
Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)&nbsp;Exhibits </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release, dated May 12, 2011.</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: May&nbsp;12, 2011 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARROWHEAD RESEARCH CORPORATION</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Kenneth
Myszkowski</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Kenneth Myszkowski</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Financial Officer</FONT></TD></TR></TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">

<IMG SRC="g186576g63u48.jpg" ALT="LOGO"> </FONT></P>
 <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="28%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PRESS RELEASE</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">May&nbsp;12, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT><BR> <P STYLE="margin-bottom:0px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P>
<P STYLE="margin-bottom:0px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P> <P STYLE="margin-bottom:0px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P>
<P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Investor&nbsp;Relations&nbsp;Contact:</B></FONT><BR>
<P STYLE="margin-bottom:0px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Brandi&nbsp;Floberg</FONT></P>
<P STYLE="margin-bottom:0px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Piacente Group, Inc.</FONT></P> <P STYLE="margin-bottom:0px; margin-top:0px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">212-481-2050</FONT></P> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">ir@arrowres.com</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT><BR> <P STYLE="margin-bottom:0px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P>
<P STYLE="margin-bottom:0px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P> <P STYLE="margin-bottom:0px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P>
<P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>ARROWHEAD REPORTS FISCAL 2011 SECOND QUARTER FINANCIAL RESULTS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>PASADENA, Calif. &#150; May&nbsp;12, 2011 &#150; Arrowhead Research Corporation (NASDAQ: ARWR)</B>, a nanomedicine company with development programs in oncology, obesity, and regenerative medicine,
today announced financial results for its fiscal 2011 second quarter ended March&nbsp;31, 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Since re-emerging
as a more focused nanomedicine company with the divestiture of Unidym, we have increased our operational efficiencies and the flexibility of our cost structure. At the same time, we are making steady progress across each of our businesses,&#148;
said Christopher Anzalone, Arrowhead&#146;s Chief Executive Officer. &#147;Data from Calando&#146;s Phase 1 trial has validated the RONDEL<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> system&#146;s ability to deliver active siRNA molecules to tumor cells and to mediate target gene knockdown. This success is vital to Calando and to the broader field
of RNAi, which hinges on the development of an effective systemic delivery technology. We are taking next steps to build on this success and push our platform into the marketplace. Specifically, we are focused on adding to our data set by treating
more patients, completing the Phase 1 to establish a safety profile, working toward developing a second clinical candidate, and establishing a commercial partnership to speed future development and defray costs. We have made progress on all of these
fronts. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Central to these efforts is expanding our R&amp;D capabilities and establishing a new Calando Scientific Advisory Board of RNAi
experts,&#148; Dr.&nbsp;Anzalone continued. &#147;Last month we announced RNAi industry expert and Calando co-founder John Rossi as the first appointment to this new SAB. We are delighted to benefit from his expertise and leadership, and we welcome
Dr.&nbsp;Rossi&#146;s guidance as an active contributor to further development of CALAA-01, and expansion </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of the RONDEL platform. We expect to bring new experts onto the Calando SAB shortly, and this move reflects our confidence in RONDEL and the market opportunities it enables. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;We are looking to bring Ablaris&#146; first anti-obesity compound into the clinic later this year, and MD Anderson is spearheading final toxicity
studies to complete the pre-clinical package. In addition to the exciting implications of Ablaris&#146; technology and addressable market opportunity, we are also pleased that this Phase 1 will be at no additional direct cost to Arrowhead beyond our
initial investment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;We are focused on completing the Calando trial and partnering this program, as well as driving the Ablaris and
Nanotope platforms forward. Current financial resources provide us with approximately 12 months of operating runway. We believe that we have a compelling set of technologies that are directed at attractive market opportunities and that we are well
positioned to realize substantial value from our nanomedicine programs,&#148; concluded Dr.&nbsp;Anzalone. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THIRD QUARTER FISCAL 2011 AND
RECENT COMPANY HIGHLIGHTS </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#149;</B></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Business highlights: </B></FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#161;</FONT>
</SUP>&nbsp;</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Began formation of Calando Scientific Advisory Board with the appointment of John J. Rossi, Ph.D. to guide future development of CALAA-01, contribute
to partnering activities, initiate new clinical candidates, and expand the RONDEL&#153; delivery system. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#161;</FONT>
</SUP>&nbsp;</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increased Arrowhead&#146;s investment in Ablaris Therapeutics to $1.3 million, secured an additional $1.6 million of outside capital, and retained 64%
equity in the company. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#161;</FONT>
</SUP>&nbsp;</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increased investment in Calando Pharmaceuticals via debt conversion and the purchase of preferred stock. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#161;</FONT>
</SUP>&nbsp;</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Completed sale of Unidym to Wisepower Co., Ltd., a publicly-traded, Seoul, Korea-based electronics company, for an upfront payment of $5.0 million in
Wisepower stock and convertible bonds, retaining upside potential for Unidym stockholders, including Arrowhead, with up to $140 million in earn-out payments and substantially reducing Arrowhead&#146;s burn rate. </FONT></P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SELECTED FINANCIAL RESULTS </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In January 2011, Arrowhead completed the sale of its ownership interests in Unidym for which Arrowhead recorded a gain on disposition of $3.9 million. Operations including revenue and expenses associated
with Unidym have been restated and are now classified as discontinued operations in the Company&#146;s financial statements. The following information reflects Arrowhead&#146;s financial results from continuing operations unless otherwise noted.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">No revenue was recorded for the three months ended March&nbsp;31, 2011 and 2010. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Total operating expenses for the quarter ended March&nbsp;31, 2011 were $1.8 million, compared with $1.4 million for the quarter ended March&nbsp;31, 2010. The increase in operating expenses was primarily
due to an increase in patent expense related to foreign patent filings and attorney fees associated with Calando&#146;s intellectual property portfolio and higher professional/outside services expense associated with consulting fees and one-time
costs incurred as a result of the Ablaris financing in January. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss from continuing operations attributable to Arrowhead for the fiscal 2011
second quarter was $1.1 million, or $0.01 per share, compared with a loss of $1.5 million, or $0.02 per share in the comparable period in fiscal 2010. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Total net income attributable to Arrowhead for the quarter ended March&nbsp;31, 2011, which includes discontinued operations and the aforementioned $3.9 million gain on disposal of discontinued
operations, was $2.9 million, or $0.04 per share based on 71.8&nbsp;million weighted average shares outstanding. This compares with a total net loss attributable to Arrowhead of $1.9 million, or $0.03 per share based on 62.9&nbsp;million weighted
average shares outstanding, for the quarter ended March&nbsp;31, 2010. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONFERENCE CALL </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management will host a conference call today, Thursday, May&nbsp;12, 2011 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the
conference call, please dial 877-407-4134 (toll free from the US and Canada), or 201-689-8430 (for international callers). Investors may also access a live audio webcast of this conference call on the Company&#146;s website at
www.arrowheadresearch.com. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A replay of the webcast will be available approximately two hours after the conclusion of the call. The
webcast archive will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be made available until Thursday, May&nbsp;19, 2011. The audio replay can be accessed by
dialing 877-660-6853 (toll free from the US and Canada), or 201-612-7415 (for international callers) and entering account number 356 and passcode 371945. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>ABOUT ARROWHEAD RESEARCH CORPORATION </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arrowhead Research Corporation (NASDAQ: ARWR) is a
nanomedicine company developing innovative therapeutic products at the interface of biology and nanoengineering to cure disease and improve human health. Arrowhead addresses its target markets through focused subsidiaries, which include: Calando
Pharmaceuticals, a leader in delivering small RNAs for gene silencing; Ablaris Therapeutics, an anti-obesity therapeutics company; and Nanotope, a regenerative medicine company. For more information please visit
<U>http://www.arrowheadresearch.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Safe Harbor Statement under the Private Securities Litigation Reform Act: </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This news release contains forward-looking statements within the meaning of the &#147;safe harbor&#148; provisions of the Private Securities Litigation
Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various
factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the
enforcement of our intellectual property rights. Arrowhead Research Corporation&#146;s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business,
results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I># # # </I></FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g186576g63u48.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g186576g63u48.jpg
M_]C_X``02D9)1@`!`0$`W`#<``#_VP!#``(!`0$!`0(!`0$"`@("`@0#`@("
M`@4$!`,$!@4&!@8%!@8&!PD(!@<)!P8&"`L("0H*"@H*!@@+#`L*#`D*"@K_
MVP!#`0("`@("`@4#`P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P``1"`!>`*@#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_****`"B
MBB@`HHHH`****`"BBD=P@+-T'4T`+17G&G?M-^"]3\8)X4A\+^)TBE<)%K$_
MAZ=+5F.`!DC>HR<;F0*,$D@<UZ,"#TI*49;,YL/C,+BTW1FI6T=F+1113.D*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`-?.?[?OQ<\5:7X.7X2
M?#O1KJ\N];B=-;GM;+3KQ(+0@`P20WMQ$K><&(Z,`JMD?,IKVWXH>,Y_A[\/
M]6\:67A?4M;N-.LGEM='TBT>>YO)<?)$B(K'+,0,XPH)8X`)K\N/'O@[XZ_&
M_P")%[XY\>?\$T-;U#7=>OE:[OKR;7H49SA%!8S*D2*`JCHJ*H'`%<F*JRA'
MECN_Z[,^?XBJ5Y8)X:C?FGHVKII=;-1E9O;TV(_^%.>(0OF'X+VN"2,_\*M\
M(<GO_P`OGN*^^_V(/B_XF\=_#A?!?Q!TR]MM;T%1%YVH0V,!O;;)\MTBLYY4
M0(NV,C(Z*?XL5R?BW_@G/\%'_95B^%>B_!K0[G6-*635[&S_`+1O$AGU9H0L
MB?:/-6?RGVK&-SX`2-B#L`KY`^"</QY_9_\`B38_$WX;?\$T/$.G:G8EXS+!
M_;S>9$ZE9(RLDC(P*DXW*P#!6QE17/%U<--<VS]?\CY?*\EQ/#6/A5CS.,E:
M2YI27GIR;I[:K[FS]6J*S_"FOQ^*?#=AXDBTV]LEO[..<6>I6K07$&]0WERQ
MMRCKG!4]"#6A7I[GZ.FFKH****!A1110`4444`%%%%`!1110`4444`%%%%`!
M2,<*32U\>_\`!8S_`(*+?#[]A'X'6'AKQ#%XAEUOXC+?:;I)\+WR6EY9V\<2
M"YO(YY(I$C>,S0JN5+;I0R_<.-J%"KB:RI4U=LY<9BZ&`PTJ]9VC'<^;_P#@
MIY^VM^S=^T3\1T^%$?[1>JZ9HG@V]FAN;33/!QOH+S4E9HY)Q+]JB$BHN8T(
M3',A#,'%>O\`_!([]C3X=:;#'^U[9>*M0\00WL$MMX0?5/#ZZ>85RT<]T$\Z
M4MN`:)&ROR^9PP92/QZ@^/G_``3Z2X26?X7?&:5`X+QGQYI0WC/(R-,R,^M?
MJ+^PM_P<"?!SX_?&[P#^Q]\._P!DS4/"UGJTD>D:1,/$<4D&GPQ0,441K`I*
MJD84`$=J]/%<.XFE'VBIMVU;=M+?,^-RWB++<7CN:O4BI-I12YG=O1>1^F>.
M,5^<G_!6?]C/X6^#_$,_[66I>,]2\.:-JL\-OXABTCPI_:*QWK;@+I\7$7E+
M)A5)P09.2=T@%?HV#D9K\GOVUO\`@X/_`&?[?Q7\3_V-OBK^QYJOB#2]+UW5
M?"^KSKXHAC6Z%M<R6YG0&`F)MT8D0Y)1@I!R,UY^%R^MF$^2G#FMJSZ/.\;@
M,%A?]IFHW^&Z;U^6IVO_``2?_;4_9]^&/C!?V9H/C]J>M6OBS4D_X1N#5O"P
MT^*SOV!!C$IN9?\`7D(JIC'F;0.7;/Z5@Y%?S%6'[0O[!>EWL.I:;X`^-=O<
MVTJRV]Q#X]TI'B=2"KJPTW*L"`01T-?O#_P2V_X*`>`O^"@O[.8\>>%[?4[;
M5?#EZ-'\0V>M7$,MTTZ1(R7+-"B(PF0A\JB*'$BA<)D]N.R;$8"DI\KY=M>A
MY?#W$&&Q\WAN=<VZ2OJNN_8^E:***\D^M"BBB@`HHHH`****`"BBJFO:UI'A
MO1;OQ%K^I0V=A86TEQ>W=S($C@A12SR.QX554$DGH!1N)M)79;HKY3_X)Y?\
M%5?`/[?WC#Q9X)L/A3K?@F_T:T@UCPU;^(I1YGB3P_/))'#JL";5(C+1@.HW
MJADC&]B>/1/"/_!1;]A'QY9ZQ?\`@W]KKX?ZI%X?T=]6UM[+Q/;R"RL$D2-[
MF3#?+$KR1J7/`+J">1734P>*I5'"4'=6OUWVV.:ECL)6IJI&:L[VUMMON>T4
M5X]I?_!0?]AS6_AYK/Q9TG]K+P!<>&_#UQ#!KFLQ>*+8P64LP)ACD;?\KR;6
MV+U?:=H.#4O@/]O3]C'XH:#I'B;P#^TUX,U2RUWQ%#H&E2VVN19GU68%H;':
M3N6X<*Q6)@&8`D`U#PV(2;Y'IY,M8K#-KWUKYH]<KY3_`."J/_!*GX;?\%0/
MA_X?T3Q'\0M0\(^(_"5S<R>'/$5I9B[CB2X\H7$4UL7C$R-Y$1!#HRL@(;!9
M6]LC_:J_9LEN/&UI%\<O"K2?#:+S?'R+K41/A]-KL6N^?W`Q')]['W&]*\.\
M!?\`!8S]CC7?COX_^"WQ)^+7A#P5%X2O-*3P]KFO^,+>*'Q/;WUDEVMS;B0(
M%C59(QG<P.\'(S6^%IX^C5]M0BU*.M[;7M]^_P!S['+C9Y;B*/L,1*+C/2S>
M]ORM;[UW/A?_`(A(;G_I(3_YBK_[ZUZC^Q3_`,&VEQ^Q_P#M3^"_VEF_;3_X
M2,>$=4:\.B?\*[^R?:\Q21[/._M"3R_OYSL;IC'-?>?Q?_;E_8W^`7BE?`WQ
MJ_:>\"^&-::V2X_LC6O$MO!<K$_W)#$S;E5NQ(`/:LWQA_P44_80^'?C:[^&
M_C[]KKX>Z)KMA="WOM+U7Q3;6\UM*<'9()'&PX(ZXZUZ,LWSZO3<7)M23^RM
M5L^AY,,@X9PU53C&*E%K[3T?3[1[,!QUK\F/VC/^#7NX^/W[0GCOX[C]N?\`
ML@>-?&>J:\-*_P"%:^?]B^V7<MQY/F_VDGF;/,V[]J[MN=HS@?>'[7G_``49
M_94_8\\&>)K_`,?_`!H\('Q7H?A:ZU?3?`=SXJMK?4M5>.W>6&WCC)9U:<J$
M1MAR7&`W2JWQ`_;PTWP'_P`$W;?_`(*(2_#6>YM9OASIGBS_`(15-45)`EY!
M!*+?[1Y9!*^?C?LYV_=&>.3`U<TP34\/>/.U%.RU[+5?B=^8T,GS%.GBK2Y$
MY6N]%U>A^<Q_X-(;H]/^"A'_`)BK_P"^M?H=_P`$T?\`@F_\,O\`@FG\$+KX
M4>!O%5]XBU+6-2_M#Q'XCU"W2%[RX$:QJL<2$^5"JK\L99R"[DN<UY?X0_X*
MS_&?2]7^%NH?M)?\$^]=\!^$/C!XETG0/!OBRT^(FDZP)+[4U#68EM862:.)
MERS.1E`N"NXA3]!77[=_[&%E\5D^!-S^U)X$_P"$R?5UTH>&4\36[WHOFD\L
M6IB5RPFWG;Y9&X-P1FNC'8O.\33]E7?-'?3E:T\X]CDRW+^'L'6]MAHJ,EI=
M\R>O;F[GK5%>,^$/^"B7["7Q`\=6?PQ\!_M<_#W6?$&HWPL[#2-*\4VUQ-=3
MDX$<81SO;([9JYIW[>/[%VL?$X_!31OVH_`E[XM6\EM&\.V7B6WENA<1!C)$
M8T8D.@1MR]5VG(&*\IX?$)V<'WV>Q[BQ6&:OSKMNMSUJBO'/AI_P4)_89^,G
MC6R^&_PK_:T^'^O:_J3,NG:-IGBBVDN;IE4LRQQAMSD*I.%!.`3VJQX*_;T_
M8L^(OC*[^'G@C]J?P)J>N6,-U+=Z5:^)K<SQ1VP9KAF3?D"-59G/\(5B<`$T
M/#8A7O!Z>3!8K#.UIK7S1ZW17RM^T!_P5Z_8[^&/P$\<?&#X+_%WPA\4M4\#
M:-'J=]X5\*^+[=YY;8WMM:-)OC$@5%>YCRVTC)`_B!KUOX!_MF_LK_M/7=QI
M/P%_:"\'^+=1LK-;G4--\/\`B""ZN+6-B!O=$8L%W,%W8QD@=352PF*A3]I*
M#2[V]/\`-$QQF%G4]G&:;]?7_)GIU%%%<YTA7@W_``4?_9]^/7[5G[,E]^SE
M\"/&ND>'!XQU.UT[QIK>I74T<MMX>=\WZVJQ12"6XDC`B$<FR-DED!=>,^\T
M5I2JRHU54CNG<SK4HUZ3IRV>C/@'3O\`@C=\1/V;OVA_A%^T?^R/^T[XJU_4
M/`CQ>'=>T7XN>)Q-:R>#S$\;V%H;.Q!1HMP>*)QY0<*V5*#<GPW_`."0OC/P
MI_P2-;]CO7K+P#/\8XO`>M^&K/QK#).UI%;7VL3WX@%RUL+@0G?&741??3@'
M`)^_Z*['FF,?+>6J:=^NE[7\M6<"RC`IRM'1IJU^]KV\]$?%_P"T[_P2]U?X
M@?"_X;^+/@39^!='^*_@'Q9X7\2ZI>:W82G3?%=WH]DUI%!>S0IYVQ4=O+EV
M,R*"H4;R5X#QE_P26_:/^.]K\=_CI\7?'/@CPY\6OB/>^'=3^'UMX+GNY-,\
M+ZGH*DV%X]Y-`DTLTG^JDE6`&..278'WA%_0^D;TSUHAF>+IQ23VZ];73MZ7
M2_+8=3*<%4DVU\NE[-7];-_GN?E=XD_X(,_M`Z_8>$99?C'X7_M/Q\)X/VM+
MV*]NX/\`A*()O$,&M,VGA+?F=666W$D@AS$$'RAF4>Q?&G_@EW\:OB'X._;!
M\+^']=\&0#X^3Z$_@5+F[N5CT];&UBB8786V/E?-'E/*$O`&=IXKV'P1^U/X
MO\2?&@^`]5^*G@*VE_X3O5=%_P"$'&CW1UG[';?:?*N?,6Z=5+K#')N>!(RK
M$!@2F>/\!?MS_$[Q%X:\.:]!\2OAQXCU#6?!-_K&M^&M`T>XCNO#]Q#IC72Q
MSG[?,=HF`A8,D9)X!4\5G+/\5)J[V?9?S1?YI+T5MCY59EPY3LDI>\W'=/9*
M#TYK_P#+R]K<UVY-+<\5\>_\$COVQ_"?[1'BGXX_`/XQ:=/!XZT70H]:TX_%
M7Q!X5ELKO3[!+0J)=,@F%["VPNAE6-H]Y4#J6I_M>_\`!+7_`(*1_M%7'Q<\
M+7_QXT3Q5H'CO6)IO![:Y\7O$.D6_AZP8HT-E)H]G92V=T(2H'F.V92H=@&)
MKW+2/VU/VH&\)^))]8\&Z5#K>GZ=X<FTO3[SPZMM+/)J5_#;NT4(U>474`CF
M&R7S8%$H*.058+T>O?M(_M,^`+31+7XV77@WP#'K?BRZLH/$/BC2`(([&+3%
MG1Y88-6D2.5[D31+FZ.553L!.*(<08F,HSMJDE>WFDOR_P`S-9ID-6DVH55%
MZO2R3E*4+-MV5Y7W=EW1X#XU_P""7/[<'@>3XP0?L]>)_A)K5K\>?A1I7A3Q
MB?&]UJ5I=Z%/::&=)9[*>VMYA<1,&:7$B1G(08&W+>Z?%3]B'XL>./\`@C_:
M_L`:3KWAZ/QE#\(M&\+/J5Q=SC3#>6EM;122"183+Y1:%RK>5N((RHY`S]7_
M`&TOC\WA#0M?\(:9I.OQSQ^++C4]5\,^$WODNK/2=2M[6"ZM[=]5@/ER1S;V
MVS3,3MV*1DC7MOVZ/&EG?^#)]9\*6\^C)HFF-\3M<T;1[J[L=/OKZU63$%Y"
MSV\<5L7@EE,DC!H;I"CDHP;&6=5)N#D]8N+3MU25ON21K2SSAV,IQ]]*22U6
MEJEI.SN]N:[>R2=MCQ7P]_P1(\.?`#XJ?`/]HS]ECX??#FQ\7^`X[6S^*6E>
M(/M,NGZY";=%N+^SD:&5K>_BF5I(9%CBW;QO9538V7^S3_P28_:\_9.^-K1^
M#/B[::_\.YOB4_B"=IOBWX@TFYELYITDECN=*M[>2RO9@BE69Y$6<`!P@Z?2
MFH_'#]I'P?X>^*_B#Q%KW@_4Q\/;J*RT^"R\*7=K]LEDL;"\$S,U_+A`+MXR
M@&24#;QRM8_BG]L;Q]HOQ$UGPW'\1_`%M=:;\2M/\/V/@6[TF=M7O[&>ZLX7
MNDD^W+SY=Q+("+=E`BYR,FM99[BN5QG*]U;7?=]?+6W_``Q57,,APS4ITY0:
M;T]U;<T7UL[^S>BNW:Z6IX%^SM_P3"_;R^"GQ+^'EE\./'/AOX4_#WPKXL34
M-<\.>$?C3XHU^UO--+RR7&FQ:;J5K';(L[R',Q;>A8R#<PY@_8]_X)+?MQ_L
M<:A9_#;P1^T#83>$=)N-4.C>(H?B5KT$D`N%G,%Q)X=\A].GDCEE1VC,P1RN
M3\W)^FO#/[6GQDF\9:5X7\6?"^V@LM>^)FI:)HGB*PCEFM9;*TOKRV>.<;LV
MUV!;(ZEMT4JLQ7#*47Z/K59WB:RDM+/?3UUUU>[/2RREE&91YZ'-[CZWC:Z3
MM:RT:2>BVLT]3\O_``=_P2@_X*+ZK\2O@KXJ^.WQ:\/>))?AG\2]/\1^(/$N
MJ?&GQ+JTNJPP2L9!!IEW8BUM964KC8X`V;=V&)KV#X._\$C8%_8B\5_LY_'2
M;PQ_PFFJWGC1?"_C?1;9[R30;?77D#&)IHX7RT;(LT:[5<*4WD'=7W!13JYK
MC*EM4K:Z*VU_\WIL>G2R?`TFW9N]]W?>W^2UW/SX\:?L*?\`!23XG?\`!.K7
MO^"=GC2/X%VVDVWP_P!.T#PEXFT/6M7BGN9K&[LC%)=P/8LD*O;P2LYB:0^;
MMPH5B5]XTO\`9!^(>G_\%.[']M(ZEH0\,6_[/H\#3V23R_V@^I#5UO/-V>5Y
M9@\I=NXR;]V!LQ\U?1]%9RQ]>2:T2=]E_-:_Y(UCEV'C)/5M6M=_RWM^;`=*
M***XCO"BBB@`HHHH`*,`T44`)L3.=HS0$0=%'Y4M%`K(38G]T4,BM]Y0:6B@
M=D($0=%'Y4!5`P%%+10*R$*(>JB@HAY*#\J6B@=D)M7^Z/RI:**`"BBB@`HH
)HH`****`/__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
